Market Overview

Cancer Clinical Trials Expert Dr. Santosh Kesari to Assist Regen BioPharma, Inc. in Addressing FDA Questions Regarding Planned dCellVax Immunotherapy Clinical Trial for Breast Cancer


SAN DIEGO, Calif., June 10, 2015 /PRNewswire/ -- Regen BioPharma, Inc. (OTCBB: RGBP) (OTC: RGBP) announced today the initiation of a collaboration with Dr. Santosh Kesari , Professor and Director of Neuro-oncology at University of California San Diego . The goals  of the collaboration is to  address  questions  posed by the FDA regarding  Regn BioPharma, Inc.'s planned  Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer and to modify the existing Investigational New Drug application in order to maximize the probability  of clinical trial success . The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 months.

"Using the immune system to treat cancer offers great potential in that the immune system destroys tumor cells, but then establishes immunological memory, which constantly patrols the body for rogue cells." Said Dr. Kesari, "Having served as a member of Regen's Scientific Advisory Board,  I am excited to be involved in this collaboration, in which we aim to help expediently address the questions posed by the FDA and allow for clinical entry of dCellVax."  

"As a company we have been fortunate to attract collaborators with established track records of bringing drugs from bench to bedside." Said Thomas Ichim, Ph.D, Chief Scientific Officer of Regen BioPharma.  "In addition to being an internationally renowned clinician, having participated in over 50 clinical trials, Dr. Kesari has been the author of over 200 scientific publications and is the inventor on numerous patents and patent applications in the area of oncology and immunology.  This combination of academic and clinical success is ideal for the current collaboration in which we are trying to address issues at the intersection between basic science and applied medicine. This  collaboration will  provide us the benefit of  Dr. Kesari's  years of expertise in oncology drug development and clinical practice."

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) (OTC PINK: RGBP). The Company is focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia. Regen is majority controlled by Bio-Matrix Scientific Group Inc. (OTC PINK: BMSN).

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer

To view the original version on PR Newswire, visit:

SOURCE Regen BioPharma, Inc.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at